市場調査レポート
商品コード
1510612

欧州のバイオプロダクション市場予測（～2030年）：地域別分析 - 製品、用途、装置、エンドユーザー別

Europe Bioproduction Market Forecast to 2030 - Regional Analysis - by Product, Application, Equipment, and End User
表紙：欧州のバイオプロダクション市場予測（～2030年）：地域別分析 - 製品、用途、装置、エンドユーザー別

出版日
ページ情報
英文 113 Pages
納期
即納可能
欧州のバイオプロダクション市場予測（～2030年）：地域別分析 - 製品、用途、装置、エンドユーザー別
出版日: 2024年05月07日
発行: The Insight Partners
ページ情報: 英文 113 Pages
納期: 即納可能
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

欧州のバイオプロダクションの市場規模は、2022年に55億1,506万米ドルに達し、2022年～2030年にCAGR13.1%で成長し、2030年には147億8,980万米ドルに達すると予測されます。

慢性疾患の増加が欧州のバイオプロダクション市場を牽引

心血管疾患（CVDs）、神経疾患、自己免疫疾患、がんは、世界的に死亡や障害を引き起こす慢性疾患のひとつです。世界保健機関（WHO）によると、CVDは世界的に死因の第1位で、毎年推定1,790万人の命を奪っています。がんもまた、世界の主要な死亡原因のひとつであり、膨大な人口に影響を及ぼしているため、社会にとって大きな経済的負担となっています。WHOによれば、2020年には、がんによる死亡者数は世界で1,000万人に達するといいます。しかし、この病気に対する効果的な治療法を開発するための研究が活発化していることは、市場の成長にプラスの影響を与えています。例えば、ノバルティスのKymriahはびまん性大細胞型B細胞リンパ腫の治療に使用されています。

さらに、患者、専門医、プライマリケア医、その他の医療専門家によって、バイオシミラーが有効かつ安全な薬剤であると認識されていることが、バイオシミラーの需要を促進しています。加えて、バイオシミラー医薬品は数百万人の患者の生活改善に貢献する一方、年間数十億米ドルのヘルスケアシステムの節約にもなっています。バイオシミラー医薬品は、クローン病、乾癬、過敏性腸症候群、大腸炎などの慢性皮膚疾患や腸疾患、糖尿病、自己免疫疾患、がん、腎臓疾患、関節炎など、多くの疾患の治療に有効で費用対効果の高い選択肢です。

慢性疾患の有病率が高い割合で増加しているため、生命を脅かす病気の治療におけるバイオプロダクションの需要は過去5年間で急速に進展し、バイオプロダクション市場を牽引しています。

欧州のバイオプロダクション市場概要

欧州のバイオプロダクション市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。欧州は世界のバイオプロダクション市場で重要な位置を占めており、2022年～2030年に注目すべきCAGRを記録すると推定されています。慢性疾患の有病率の増加により、技術進歩や投資とともに製品の上市や承認が増加しており、同地域の市場成長に寄与しています。

バイオシミラーは競合を導入し、生物製剤の購入しやすさを向上させ、最終的には患者の治療とヘルスケア業界を支援するための節約と付加価値サービスを提供します。ヘルスケア専門家は、高品質の生物製剤でより多くの患者を低コストで治療することができます。コスト削減の可能性が大きいことから、ドイツ保健省はバイオシミラーの採用を拡大するための新法を導入しました。バイオシミラーの薬剤師による代替を認めている欧州連合（EU）諸国は少数であるため、これは特にドイツにとって、実務の大きな変化を意味します。さらに、PHI整形外科理学療法センター、ジャーマンインターナショナルクリニック（ドイツ、フランクフルト）、CBCヘルスミュンヘン（ドイツ）などのヘルスケアプロバイダーは、糖尿病性網膜症、視神経炎、関節リウマチなどのさまざまな慢性疾患に対して幹細胞療法を提供しています。このため、今後数年間は細胞治療の採用が増加すると予想されます。また、国際的な企業間の提携の増加も市場の成長を後押ししています。例えば、2020年11月、日立化成アドバンスト・セラピューティクス・ソリューションズLLCとapceth Biopharma GmbHは、輸血依存性B型サラセミア（TDT）に対する1回限りの遺伝子治療薬であるZYNTEGLOの欧州における商業用医薬品製造能力の拡大を含む、複数の治療薬の臨床および商業用供給に関する長期開発・製造サービス契約を締結し、bluebird bioとの関係を拡大しました。このため、ドイツではバイオシミラーの採用に向けた政府の取り組みが活発化しており、市場の繁栄が期待されています。

欧州のバイオプロダクション市場の収益と2030年までの予測（金額）

欧州のバイオプロダクション市場のセグメンテーション

欧州のバイオプロダクション市場は、製品、用途、装置、エンドユーザー、国に分類されます。

製品別に見ると、欧州のバイオプロダクション市場は、生物製剤とバイオシミラー、ワクチン、細胞・遺伝子治療薬、核酸治療薬、その他に区分されます。生物製剤とバイオシミラーセグメントは、2022年に欧州のバイオプロダクション市場で最大のシェアを占めました。

用途別では、欧州のバイオプロダクション市場は、関節リウマチ、血液疾患、がん、糖尿病、心血管疾患、その他に区分されます。2022年の欧州のバイオプロダクション市場シェアは、がんセグメントが最大でした。

装置別では、欧州のバイオプロダクション市場は上流装置、下流装置、バイオリアクター、消耗品・付属品に分けられます。消耗品・付属品セグメントは2022年に欧州のバイオプロダクション市場で最大のシェアを占めました。

エンドユーザー別では、欧州のバイオプロダクション市場はバイオ製薬会社、受託製造機関、その他に分類されます。バイオ製薬会社セグメントは2022年に欧州のバイオプロダクション市場で最大のシェアを占めました。

国別では、欧州のバイオプロダクション市場はドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。2022年の欧州のバイオプロダクション市場シェアはドイツが独占。

Lonza Group AG、bbi-biotech GmbH、Danaher Corp、Sartorius AG、FUJIFILM Irvine Scientific Inc、Thermo Fisher Scientific Inc、Merck KGaA、F. Hoffmann-La Roche Ltd、Bio-Rad Laboratories Inc.は、欧州のバイオプロダクション市場で事業を展開する大手企業の一部です。

目次

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州のバイオプロダクション市場- 主要産業力学

  • 市場促進要因
    • 再生医療の採用増加
    • 慢性疾患の増加
  • 市場抑制要因
    • 細胞療法とバイオシミラー製造の高コスト
  • 市場機会
    • ブロックバスター生物製剤の特許切れ
  • 今後の動向
    • 細胞療法製造の自動化へのシフト
  • 影響分析

第5章 バイオプロダクション市場- 欧州市場分析

  • 欧州のバイオプロダクション市場収益（2020年～2030年）

第6章 欧州のバイオプロダクション市場 - 2030年までの収益と予測：製品別

  • 欧州のバイオプロダクション市場の収益シェア：製品別（2022年・2030年）
  • 生物製剤とバイオシミラー
  • ワクチン
  • 細胞・遺伝子治療薬
  • 核酸治療薬
  • その他

第7章 欧州のバイオ医薬品市場 - 2030年までの収益と予測：用途別

  • 欧州のバイオプロダクション市場の収益シェア：用途別（2022年・2030年）
  • がん
  • 心血管疾患
  • 関節リウマチ
  • 血液疾患
  • 糖尿病
  • その他

第8章 欧州のバイオプロダクション市場 - 2030年までの収益と予測：装置別

  • 欧州のバイオプロダクション市場の収益シェア：装置別（2022年・2030年）
  • 消耗品および付属品
  • 下流装置
  • バイオリアクター
  • 上流装置

第9章 欧州のバイオプロダクション市場 - 2030年までの収益と予測：エンドユーザー別

  • 欧州のバイオプロダクション市場の収益シェア：エンドユーザー別（2022年・2030年）
  • バイオ医薬品企業
  • 製造受託機関
  • その他

第10章 欧州のバイオプロダクション市場 - 2030年までの収益と予測：国別分析

  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州

第11章 バイオプロダクション市場-業界情勢

  • バイオプロダクション市場の成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第12章 企業プロファイル

  • . Lonza Group AG
  • bbi-biotech GmbH
  • Danaher Corp
  • Sartorius AG
  • FUJIFILM Irvine Scientific Inc
  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Bio-Rad Laboratories Inc

第13章 付録

図表

List Of Tables

  • Table 1. Europe Bioproduction Market Segmentation
  • Table 2. Europe Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Germany Bioproduction Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. Germany Bioproduction Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. Germany Bioproduction Market, by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Germany Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Germany Bioproduction Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. UK Bioproduction Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. UK Bioproduction Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. UK Bioproduction Market, by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. UK Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. UK Bioproduction Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. France Bioproduction Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. France Bioproduction Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. France Bioproduction Market, by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. France Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. France Bioproduction Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Italy Bioproduction Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Italy Bioproduction Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Italy Bioproduction Market, by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Italy Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Italy Bioproduction Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. Spain Bioproduction Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. Spain Bioproduction Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. Spain Bioproduction Market, by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 26. Spain Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Spain Bioproduction Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Rest of Europe Bioproduction Market, by Product - Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Rest of Europe Bioproduction Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Rest of Europe Bioproduction Market, by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 31. Rest of Europe Bioproduction Market, For Bioreactors by Equipment - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. Rest of Europe Bioproduction Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 33. Recent Inorganic Growth Strategies in the Bioproduction Market
  • Table 34. Recent Organic Growth Strategies in the Bioproduction Market
  • Table 35. Glossary of Terms, Bioproduction Market

List Of Figures

  • Figure 1. Europe Bioproduction Market Segmentation, By Country
  • Figure 2. Europe Bioproduction Market: Key Industry Dynamics
  • Figure 3. Europe Bioproduction Market: Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Bioproduction Market Revenue (US$ Mn), 2020 - 2030
  • Figure 5. Europe Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
  • Figure 6. Biologics and Biosimilars: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Vaccines: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Cell and Gene Therapies: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Nucleic Acid Therapeutics: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Europe Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 12. Cancer: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Cardiovascular Diseases: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Rheumatoid Arthritis: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Hematological Disorders: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Diabetes: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Others: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Europe Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
  • Figure 19. Consumables and Accessories: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Downstream Equipment: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Bioreactors: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Upstream Equipment: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Europe Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
  • Figure 24. Biopharmaceutical Companies: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Contract Manufacturing Organizations: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 26. Others: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 27. Europe: Bioproduction Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 28. Europe: Bioproduction Market, by Country, 2022 & 2030 (%)
  • Figure 29. Germany: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. UK: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. France: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. Italy: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 33. Spain: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 34. Rest of Europe: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 35. Growth Strategies in the Bioproduction Market
目次
Product Code: BMIRE00030059

The Europe bioproduction market was valued at US$ 5,515.06 million in 2022 and is expected to reach US$ 14,789.80 million by 2030; it is estimated to register a CAGR of 13.1% from 2022 to 2030.

Increasing Prevalence of Chronic Diseases Drives Europe Bioproduction Market

Cardiovascular diseases (CVDs), neurological disorders, autoimmune disorders, and cancer are among the chronic diseases causing death and disabilities at a significant rate worldwide. As per the World Health Organization (WHO), CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Cancer is also among the leading causes of mortality worldwide, affecting a huge population; therefore, it acts as a huge financial burden on society. According to the WHO, in 2020, ~10 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively affecting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis' Kymriah is used to treat diffuse large B-cell lymphoma.

Moreover, recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve life of millions of patients while saving billions of dollars of the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases such as Crohn's disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis.

As the prevalence of chronic diseases is increasing at a high rate, the demand for bioproduction in treating life-threatening illnesses has progressed rapidly over the last five years, thereby driving the bioproduction market.

Europe Bioproduction Market Overview

The Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global bioproduction market and is estimated to register a notable CAGR during 2022-2030. The increasing prevalence of chronic disorders has resulted in a growing number of product launches and approvals, along with technological advancements and investment, thereby contributing to the market growth in the region.

Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare industry. Healthcare professionals can treat more patients with high-quality biologics at reduced cost. Due to the massive potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As a few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. In addition, healthcare providers such as PHI Orthopedic Physiotherapy Center, German International Clinic, Frankfurt, Germany; CBC Health Munich, Germany; and other providers offer stem cell therapy for various chronic diseases such as diabetic retinopathy, optic nerve neuritis, and rheumatoid arthritis. This is expected to increase the adoption of cell therapies in the coming years. Also, a growing number of partnerships among international players boost the market growth. For instance, in November 2020, Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including expanded commercial drug product manufacturing capacity in Europe for ZYNTEGLO, a one-time gene therapy for transfusion-dependent B-thalassemia (TDT). Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to flourish.

Europe Bioproduction Market Revenue and Forecast to 2030 (US$ Million)

Europe Bioproduction Market Segmentation

The Europe bioproduction market is categorized into product, application, equipment, end user, and country.

Based on product, the Europe bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest Europe bioproduction market share in 2022.

In terms of application, the Europe bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest Europe bioproduction market share in 2022.

By equipment, the Europe bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest Europe bioproduction market share in 2022.

In terms of end user, the Europe bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest Europe bioproduction market share in 2022.

By country, the Europe bioproduction market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe bioproduction market share in 2022.

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the Europe bioproduction market.

Table Of Contents

Table of Content

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Bioproduction Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Adoption of Regenerative Medicines
    • 4.1.2 Increasing Prevalence of Chronic Diseases
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
  • 4.3 Market Opportunities
    • 4.3.1 Patent Expiry of Blockbuster Biologics
  • 4.4 Future Trends
    • 4.4.1 Shift Toward Automated Cell Therapy Manufacturing
  • 4.5 Impact Analysis

5. Bioproduction Market - Europe Market Analysis

  • 5.1 Europe Bioproduction Market Revenue (US$ Mn), 2020 - 2030

6. Europe Bioproduction Market - Revenue and Forecast to 2030 - by Product

  • 6.1 Overview
  • 6.2 Europe Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
  • 6.3 Biologics and Biosimilars
    • 6.3.1 Overview
    • 6.3.2 Biologics and Biosimilars: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Vaccines
    • 6.4.1 Overview
    • 6.4.2 Vaccines: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Cell and Gene Therapies
    • 6.5.1 Overview
    • 6.5.2 Cell and Gene Therapies: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Nucleic Acid Therapeutics
    • 6.6.1 Overview
    • 6.6.2 Nucleic Acid Therapeutics: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.7 Others
    • 6.7.1 Overview
    • 6.7.2 Others: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Bioproduction Market - Revenue and Forecast to 2030 - by Application

  • 7.1 Overview
  • 7.2 Europe Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
  • 7.3 Cancer
    • 7.3.1 Overview
    • 7.3.2 Cancer: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Cardiovascular Diseases
    • 7.4.1 Overview
    • 7.4.2 Cardiovascular Diseases: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Rheumatoid Arthritis
    • 7.5.1 Overview
    • 7.5.2 Rheumatoid Arthritis: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Hematological Disorders
    • 7.6.1 Overview
    • 7.6.2 Hematological Disorders: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Diabetes
    • 7.7.1 Overview
    • 7.7.2 Diabetes: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.8 Others
    • 7.8.1 Overview
    • 7.8.2 Others: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Bioproduction Market - Revenue and Forecast to 2030 - by Equipment

  • 8.1 Overview
  • 8.2 Europe Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
  • 8.3 Consumables and Accessories
    • 8.3.1 Overview
    • 8.3.2 Consumables and Accessories: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Downstream Equipment
    • 8.4.1 Overview
    • 8.4.2 Downstream Equipment: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Bioreactors
    • 8.5.1 Overview
    • 8.5.2 Bioreactors: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.5.2.1 Europe: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
  • 8.6 Upstream Equipment
    • 8.6.1 Overview
    • 8.6.2 Upstream Equipment: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Bioproduction Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Europe Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Biopharmaceutical Companies
    • 9.3.1 Overview
    • 9.3.2 Biopharmaceutical Companies: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Contract Manufacturing Organizations
    • 9.4.1 Overview
    • 9.4.2 Contract Manufacturing Organizations: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: Europe Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Bioproduction Market - Revenue and Forecast to 2030 - Country Analysis

  • 10.1 Europe: Bioproduction Market
    • 10.1.1 Europe: Bioproduction Market, by Country, 2022 & 2030 (%)
      • 10.1.1.1 Germany: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.1 Germany: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.2 Germany: Bioproduction Market, by Product, 2020-2030 (US$ Million)
        • 10.1.1.1.3 Germany: Bioproduction Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.1.4 Germany: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.1.4.1 Germany: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.1.5 Germany: Bioproduction Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.2 UK: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 UK: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.3 UK: Bioproduction Market, by Product, 2020-2030 (US$ Million)
        • 10.1.1.2.4 UK: Bioproduction Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.2.5 UK: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.2.5.1 UK: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.2.6 UK: Bioproduction Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.3 France: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 France: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.3 France: Bioproduction Market, by Product, 2020-2030 (US$ Million)
        • 10.1.1.3.4 France: Bioproduction Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.3.5 France: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.3.5.1 France: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.3.6 France: Bioproduction Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.4 Italy: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.3 Italy: Bioproduction Market, by Product, 2020-2030 (US$ Million)
        • 10.1.1.4.4 Italy: Bioproduction Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.4.5 Italy: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.4.5.1 Italy: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.4.6 Italy: Bioproduction Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.5 Spain: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.3 Spain: Bioproduction Market, by Product, 2020-2030 (US$ Million)
        • 10.1.1.5.4 Spain: Bioproduction Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.5.5 Spain: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.5.5.1 Spain: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.5.6 Spain: Bioproduction Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.6 Rest of Europe: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe: Bioproduction Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.3 Rest of Europe: Bioproduction Market, by Product, 2020-2030 (US$ Million)
        • 10.1.1.6.4 Rest of Europe: Bioproduction Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.6.5 Rest of Europe: Bioproduction Market, by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.6.5.1 Rest of Europe: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
        • 10.1.1.6.6 Rest of Europe: Bioproduction Market, by End User, 2020-2030 (US$ Million)

11. Bioproduction Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Bioproduction Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 . Lonza Group AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 bbi-biotech GmbH
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Danaher Corp
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Sartorius AG
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 FUJIFILM Irvine Scientific Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Thermo Fisher Scientific Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Merck KGaA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 F. Hoffmann-La Roche Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Bio-Rad Laboratories Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms